Novocuff, Inc. is focused on developing innovative medical devices aimed at improving pregnancy outcomes, particularly for women at risk of preterm birth due to conditions such as preterm premature rupture of membranes (PPROM) and cervical shortening. The company has created the Novocuff Cervical Control System (CCS), a minimally invasive device designed to stabilize and close the cervix, thereby extending pregnancy duration. This technology addresses a significant gap in current medical interventions, as there are no reliable therapeutic or device options available for retaining amniotic fluid or prolonging latency after PPROM. Novocuff is preparing to initiate a multi-center pivotal clinical trial in the U.S. in early 2025, which will be crucial for validating the effectiveness of their device.

The mission of Novocuff is to transform the standard of care for maternal health, aiming to reduce the morbidity and mortality associated with preterm births, which affect millions of infants globally each year. The company has recently secured $26 million in Series A funding, which will support the clinical trial, regulatory submissions, and the early commercialization of their technology. By focusing on innovative solutions for critical pregnancy complications, Novocuff is positioned to make a significant impact on maternal and infant health outcomes, aligning with broader global health goals.

United States

Founded in 2003, LinkedIn connects the world's professionals to make them more productive and successful. With more than 1 billion members worldwide, including executives from every Fortune 500 company, LinkedIn is the world's largest professional network. The company has a diversified business model with revenue coming from Talent Solutions, Marketing Solutions, Sales Solutions and Premium Subscriptions products. Headquartered in Silicon Valley, LinkedIn has offices across the globe..

Novocuff, Inc.

Company Details